Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Novartis Receives FDA Approval for First Cell-Culture Influenza Vaccine

by Global Biodefense Staff
November 23, 2012

The Food and Drug Administration (FDA) this week approved the use of Novartis’ Flucelvax vaccine in adults, becoming the first cell-culture-derived influenza vaccine to receive approval in the United States. 

Traditional vaccine production methods have relied on egg-based production, requiring a large number of fertilized chicken eggs to grow strains and often needing several months for organization of egg supplies, virus incubation and actual production before a vaccine is delivered to physicians or pharmacies. 

Cell-culture technology utilizes a well-characterized mammalian cell line to grow virus strains, providing an avenue to more easily meet surge capacity needs in response to an epidemic. Cells can be frozen and stored in advance of an epidemic, or developed rapidly in response to an urgent public health need. 

Cell-culture technology is successfully used to manufacture other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. 

“Modern cell-culture technology will likely become the new standard for influenza vaccine production and we are proud to lead the way,” said Andrin Oswald, Division Head, Novartis Vaccines and Diagnostics.

The US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has provided partial funding to Novartis for the development of the cell-culture manufacturing technology, as well as for construction of a state-of-the-art production facility in Holly Springs, N.C. The Novartis facility enhances domestic pandemic preparedness capabilities and is the first of its kind in the US.

Tags: ASPRBARDAHHSInfluenzaVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC